News

https://sclerodermanews.com/wp-content/uploads/videos/Sequence%2001_1.mp4             Scleroderma News Today’s exclusive interview with Professor Christopher Denton, lead investigator of two Phase 3 clinical trials assessing Bayer’s class of sGC stimulators, Adempas, in PAH and PAH-CTD patients.   The 4th Systemic Sclerosis World Congress opened on Friday with a…

Patients with connective tissue disease or systemic sclerosis associated with pulmonary arterial hypertension (PAH) who are positive for anti-U1 RNP antibodies have more a favorable disease prognosis than patients without these antibodies, a study published in the journal Arthritis & Rheumatology showed. Anti-U1 RNP antibodies are autoantibodies directed at nuclear proteins. They are…